Icomb 2,5 Mg/2,5 Mg Capsule Rigide

Ramipril and amlodipine besilate, the active ingredients in Icomb 2,5 Mg/2,5 Mg Capsule Rigide, are an ACE inhibitor and calcium channel blocker presented as a 2.5 mg/2.5 mg hard capsule for oral use. They treat hypertension in adult patients, providing combined blood‑pressure control for essential hypertension.

GNH USA supplies Icomb 2,5 Mg/2,5 Mg Capsule Rigide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icomb combines ramipril and amlodipine besilate to target the renin‑angiotensin system and vascular calcium channels for blood‑pressure management.

- Hypertension: lowers systolic and diastolic pressure in patients with essential hypertension. - Essential hypertension: provides combined therapy to improve overall blood‑pressure control. - Cardiovascular risk reduction: helps decrease the risk of stroke and myocardial infarction associated with uncontrolled hypertension.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness: light‑headedness, especially after standing. - Peripheral edema: swelling of ankles or feet. - Headache: mild to moderate intensity. - Flushing: warmth and reddening of skin. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or throat. - Severe hypotension: markedly low blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzyme elevations. - Myocardial infarction: chest pain indicative of heart attack. - Arrhythmia: irregular heart rhythm. - Neutropenia: low white‑blood‑cell count increasing infection risk.

Before initiating therapy, consider patient‑specific factors and monitor for adverse reactions. - Monitor renal function: assess serum creatinine and potassium regularly. - Avoid in pregnancy: category D, potential fetal harm. - Caution with hepatic impairment: dose adjustment may be required. - Concomitant potassium‑sparing diuretics: increased risk of hyperkalemia. - Use cautiously in elderly: heightened sensitivity to blood‑pressure lowering effects. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Icomb may interact with several medicines; assess risk before co‑administration.

Major Interactions (Avoid): - Aliskiren in diabetic patients: risk of renal impairment and hyperkalemia. - Concurrent ARBs or other ACE inhibitors: additive effect on potassium and renal function. - Potassium supplements or salt substitutes: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Diuretics: can enhance hypotensive effect, monitor blood pressure. - CYP3A4 inhibitors (e.g., clarithromycin): increase amlodipine plasma levels. - CYP3A4 inducers (e.g., rifampicin): reduce amlodipine effectiveness. - Beta‑blockers: additive heart‑rate reduction, observe for bradycardia. - Lithium: may increase lithium concentrations, monitor serum levels.